

Procedures for Enteral and Parenteral Moderate Sedation and Emergency Management

Joseph A. Giovannitti, Jr., DMD
Professor and Chair,
Department of Dental Anesthesiology
University of Pittsburgh School of Dental Medicine
ASDA's Institute for the Management of Pain and Anxiety (IMPA)
In Collaboration with the Academy of General Dentistry
June 9 & 10, 2021



1

Disclosures

- No financial disclosures
- Representing the American Society of Dentist Anesthesiologist's Institute for the Management of Pain and Anxiety
 - ASDA/IMPA



2

Overview

Presented by the ASDA's
Institute for the Management
of Pain and Anxiety

Cutting-Edge Education for
the Cutting-Edge Dental
Professional

Spectrum of Pain Control

Overview of enteral sedation

Useful drugs for adult and pediatric enteral sedation


Useful drugs for adult moderate sedation

Emergency management and patient rescue




3

Dentists Use of Sedation on Their Patients in Their Primary Practice



4

Route of Administration



5

Universal Fears

- Pain
- The Unknown
- Helplessness, dependency
- Bodily change, mutilation
- Death



6

**“PAIN IS A THING OF
THE MIND, AND THE
MIND CAN BE
CONTROLLED”**



- Mr. Spock
Chief Science Officer
Starship Enterprise (NCC-1701)



7

Objectives of Sedation

Mood alteration

Consciousness
maintained

Cooperation


Stabilization of
vital signs

Pain threshold
elevated

Amnesia

8

Spectrum of Pain Control



9

ADA 2016

Because sedation and general anesthesia are a continuum, it is not always possible to predict how an individual patient will respond. Hence, practitioners intending to produce a given level of sedation should be able to diagnose and manage the physiologic consequences (rescue) for patients whose level of sedation becomes deeper than initially intended.



10

Advantages of Moderate Sedation

Eliminates or diminishes fear and anxiety

Altered time perception

Reduced incidence of medical emergencies

Effective time management

Improved quality of dental care

11

Indications for Moderate Sedation

- Psychological considerations
- Medical history considerations
- Procedural requirements
- Special considerations

12

Contraindications for Moderate Sedation

- Severe intellectual and/or physical disability
- Extreme behavioral management problem
- Prior history of adverse experiences
- Severe dental phobia
- Lack of proper facilities or trained personnel



13

Minimal Sedation

- A minimally depressed level of consciousness, produced by a pharmacological method, that retains the patient's ability to independently and continuously maintain an airway and respond normally to tactile stimulation and verbal command. Although cognitive function and coordination may be modestly impaired, ventilatory and cardiovascular functions are unaffected.
- Patients whose only response is reflex withdrawal from repeated painful stimuli would not be considered to be in a state of minimal sedation.



14

Minimal Sedation via the Enteral Route

- Minimal sedation may be achieved by the administration of a drug, either singly or in divided doses, by the enteral route to achieve the desired clinical effect, not to exceed the maximum recommended dose (MRD).
- The administration of enteral drugs exceeding the maximum recommended dose during a single appointment is considered to be moderate sedation and the moderate sedation guidelines apply.
- Nitrous oxide/oxygen when used in combination with sedative agent(s) may produce minimal, moderate, deep sedation or general anesthesia.
- If more than one enteral drug is administered to achieve the desired sedation effect, with or without the concomitant use of nitrous oxide, the guidelines for moderate sedation must apply.



15

Moderate Sedation

- A drug-induced depression of consciousness during which patients respond purposefully to verbal commands, either alone or accompanied by light tactile stimulation. No interventions are required to maintain a patent airway, and spontaneous ventilation is adequate. Cardiovascular function is usually maintained.
- In accord with this particular definition, the drugs and/or techniques used should carry a margin of safety wide enough to render unintended loss of consciousness unlikely.



16

Deep Sedation

- A drug-induced depression of consciousness during which patients cannot be easily aroused but respond purposefully following repeated or painful stimulation. The ability to independently maintain ventilatory function may be impaired. Patients may require assistance in maintaining a patent airway, and spontaneous ventilation may be inadequate. Cardiovascular function is usually maintained



17

General Anesthesia

- A drug-induced loss of consciousness during which patients are not arousable, even by painful stimulation. The ability to independently maintain ventilatory function is often impaired. Patients often require assistance in maintaining a patent airway, and positive pressure ventilation may be required because of depressed spontaneous ventilation or drug-induced depression of neuromuscular function. Cardiovascular function may be impaired.



18

History of Permitting

- 1970' s
 - Deaths in dental offices of untrained dentists administering GA to dental patients led to the passage of legislation requiring a 'permit' from state dental boards after demonstration of education and clinical proficiency
- Present
 - GA regulated in all 50 states
 - GA permit required in 45 states



19

With Introduction of GA Permits:

Doctors unable to qualify for GA
ceased

- ↓ deaths associated with GA

Began to employ IV, IM sedation
(unregulated)

- ↑ deaths from parenteral sedation



20

History of Permitting

States began to require permits for the administration of parenteral sedation:

- Intravenous (IV)
- Intramuscular (IM)

Present

- Parenteral sedation regulated in all states
- Parenteral sedation permit required in 45 states

21

History of Permitting

- Following introduction of parenteral sedation permits
 - Number of deaths from parenteral sedation decreased
- Doctors no longer able to administer parenteral sedation began to administer oral sedatives in an attempt to achieve sedation levels equal to that seen parenterally

22

History of Permitting

- It was assumed that orally administered agents were somehow inherently safer and not likely to produce the misadventures and catastrophic accidents responsible for patient deaths
- The number of deaths associated with oral sedation increased



23

DENTAL ANESTHESIOLOGY: A 2017 Guide to the Rules and Regulations of the United States of America

Sean G. Boynes, DMD, MS www.adsahome.org

- General anesthesia
 - 50 states regulate
 - 45 issue permits
- Parenteral conscious sedation
 - 50 states regulate
 - 45 issue permits
- Enteral conscious sedation
 - 27 states regulate and issue permits
 - 23 in 2008
- Inhalation sedation (N20-O2)
 - 50 states regulate
 - 11 issue permits
- Anesthesia-specific CE
 - 2 states in 2004
 - 29 states in 2017



24

Enteral Sedation



25

Enteral Sedation

- **Dosing for minimal sedation via the enteral route** – minimal sedation may be achieved by the administration of a drug, either singly or in divided doses, by the enteral route to achieve the desired clinical effect, not to exceed the maximum recommended dose (MRD).
- The administration of enteral drugs exceeding the maximum recommended dose during a single appointment is considered to be moderate sedation and the moderate sedation guidelines apply.
- If more than one enteral drug is administered to achieve the desired sedation effect, with or without the concomitant use of nitrous oxide, the guidelines for moderate sedation must apply.



26

Enteral Sedation

- Enteral

- Any technique of administration in which the agent is absorbed through the GI tract or oral mucosa
 - Oral
 - Rectal
 - Sublingual
 - Intranasal



27

Advantages of Oral Sedation

Ease of
administration

Low cost

Decreased
incidence of
adverse
reactions

Decreased
severity of
adverse
reactions

Decreased
severity of
allergic
reactions

Duration of
action may
extend
postoperatively



28

Disadvantages of Oral Sedation

Reliance on patient compliance

Delayed onset

Erratic and/or incomplete absorption

Inability to titrate

Inability to readily alter level of sedation

Prolonged duration of action

Usually not effective for severe anxiety

Duration of action may extend postoperatively



29

Therapeutic Suggestions for Oral Sedation

Verbal and written instructions

Bedtime dose encouraged

Administer well in advance of need

Maintain NPO status prior to premedication

Patient must be accompanied by responsible adult

Prescribe or dispense only amount of drug required

Doctor administered dose recommended

Recovery and assistance may be required



30

Uptake and Distribution of Enteral Medications

Absorption

Gastric emptying times

First-pass effect

Sublingual administration

Blood flow to sites of action

Metabolism

Drug interactions

CYP enzyme activity

31

Drug Response Variations


- Age
 - Children
 - Elderly
- Genetics
 - CYP enzymes
- Disease states
- Anxiety level
 - Physiological antagonism
- Drug interactions
 - Potentiation by CNS depressants
 - Antagonism by CNS stimulants
- Normal biologic variation
- Pharmacokinetic factors

32

Normal Biologic Variation

Dose-Response Curve:

70% respond appropriately
15% hyper-respond (sensitive)
15% hypo-respond (resistant)



33

Therapeutic Index

The ratio of the toxic dose of a drug to its therapeutic dose

- The higher the index, the safer the drug

Benzodiazepines have a high therapeutic index

34

Benzodiazepines

Facilitate binding of GABA

Favorable therapeutic index

Anterograde amnesia

Drug variability

- Onset
- Duration
- Metabolism
- Sedation vs. hypnosis



35

Benzodiazepines

Specificity of effect

Well absorbed by the oral route

High margin of safety/therapeutic index

Effective as single agents

Specific reversal agent available

- Flumazenil



36

Useful Benzodiazepines

- Alprazolam
 - Antianxiety
- Diazepam
 - Antianxiety
- Lorazepam
 - Antianxiety
 - Sedative-hypnotic
- Midazolam
 - Sedative/hypnotic
- Oxazepam
 - Antianxiety
- Triazolam
 - Sedative/hypnotic



37

The Fab Four



38

Diazepam (Valium)



- Dosage
 - 2 – 10 mg adults
 - 0.15 – 0.3 mg/kg children
- Onset
 - 1 hour
 - 2 hours peak
- Duration
 - 1 – 3 hours
- Contraindications
 - Allergy
 - Acute narrow angle glaucoma
- Precautions
 - Sedation intensified with CYP3A4 and CYP2C19 inhibitors
- Availability
 - 2, 5, 10 mg tablets
 - 10 mg/5 ml syrup
- Active metabolites
- Pregnancy category
 - D
- Classification
 - Antianxiety

39

Lorazepam (Ativan)



- Dosage
 - 2 – 4 mg adult
 - Well tolerated in the elderly
- Onset
 - 1 – 2 hours
- Duration
 - 2 – 4 hours
- Contraindications
 - Allergy
 - Acute narrow angle glaucoma
- Precautions
 - Oversedation
 - Depressive disorders
 - Psychosis
- Availability
 - 0.5, 1, 2 mg tablets
- No active metabolites
- Pregnancy category
 - D
- Classification
 - Antianxiety
 - Sedative/hypnotic

40

Triazolam (Halcion)



- Dosage
 - 0.25-0.5mg adults
- Onset
 - 1 hour
- Duration
 - 1 hour
- Contraindications
 - Pregnancy
- Precautions
 - Excessive sedation possible in elderly
- Availability
 - 0.125, 0.25 mg tablets
- No active metabolites
- Pregnancy category
 - X
- Classification
 - Sedative/hypnotic

41

Midazolam (Versed)



- Dosage
 - 0.25-1.0 mg/kg children
 - Max 20 mg
- Onset
 - 15-30 minutes
- Duration
 - 30 min-1 hour
- Contraindications
 - Allergy
 - Acute narrow angle glaucoma
- Precautions
 - Sedation intensified by CYP3A4 inhibitors
- Availability
 - 2 mg/ml syrup
- No active metabolites
- Pregnancy category
 - D

42


Oxazepam (Serax)



- Dosage
 - 10-30 mg adults
- Onset
 - 1 hour
- Duration
 - 2-4 hours
- Contraindications
 - Allergy
- Precautions
 - Same as other BNZ
- Availability
 - 10, 15, 30 mg capsules
 - 15 mg tablets
- No active metabolites
- Pregnancy category
 - D
- Classification
 - Antianxiety

43

Alprazolam (Xanax)



- Dosage
 - 0.25-1.0 mg adults
- Onset
 - 1 hour
- Duration
 - 1-2 hours
- Contraindications
 - Allergy
 - Acute narrow angle glaucoma
- Precautions
 - Sedation intensified with CYP3A4 inhibitors
- Availability
 - 0.25, 0.5, 1 mg tablets
- No active metabolites
- Pregnancy category
 - D
- Classification
 - Antianxiety

44

Diazepam/Clonidine

.15-.3 mg/kg / 0.2 mg



45

Non-Benzodiazepine Sedative/Hypnotics

Zolpidem
(Ambien)

Zaleplon
(Sonata)

Ezopiclone
(Lunesta)



46

Non-Benzodiazepine Sedative/Hypnotics

Chemically unrelated to other sedative/hypnotics

Pharmacologically similar to BNZ

GABA receptor agonist

- Sedation, amnesia
- Less memory and cognitive impairment than BNZ


Biotransformed by several CYP enzymes in addition to CYP3A4

- CYP3A4 inhibitors and inducers have a lesser effect



47

Zolpidem (Ambien)



- Dosage
 - 5-10 mg
- Onset
 - 1 hour
- Duration
 - 2-3 hours
- Contraindications
 - Allergy
- Precautions
 - Reduce dose in elderly
- Availability
 - 5, 10 mg tablets
- No active metabolites
- Pregnancy category
 - B
- Classification
 - Sedative/hypnotic

48

Zaleplon (Sonata)

- Dosage
 - 5-10 mg
- Classification
 - Sedative/hypnotic

Ezopiclone (Lunesta)

- Dosage
 - 2-3 mg
 - 1-3 mg in elderly
- Classification
 - Sedative/hypnotic

49

Melatonin Receptor Agonists

- Ramelteon (Rozerem)
 - 8 mg
- Melatonin
 - Secreted by pineal gland according to the light/dark cycle
 - Activation of melatonin receptors promotes sleep
- Uses
 - Jet lag
 - Insomnia
 - Preoperative sedation
 - Anxiolysis

50

Pediatric Enteral Sedation



51

“Why do we have to have all these kids?”



52

The Pediatric Patient



- Anxious and fearful
- Lack of past experience
- Poor coping skills
- No incentive/benefit to cooperate



53

Potential Damage to the Pediatric Psyche

Fear of the
unknown

Surprise

Pain

“Shots”

Physical
restraint

Parental
separation



54

Pediatric Stress and Anxiety

50% - 75% of children undergoing surgery develop anxiety

Associated with emergence delirium and postoperative behavioral problems



55

Goals of Pediatric Sedation

Facilitate	Facilitate the provision of quality dental care
Minimize	Minimize the extremes of disruptive behavior
Promote	Promote a positive psychological response to treatment
Promote	Promote child welfare and safety
Return	Return the child to a physiologic state in which safe discharge is possible



56

Pediatric Sedation

The first option for sedation is **NO SEDATION!**

10% - 15% of children will require sedation
Approximately 10,000 sedations per month

< 6 years of age or those with developmental delay have an increased risk profile

True moderate (conscious) sedation < 36 months is not reliable

- Deep sedation may be required

10% - 30% of enteral sedations will fail

Sedation/anesthesia is often objectionable to parents



57

Frankl Scale

An assessment of pediatric behavior

Graded 1 - 4

Worst - Best



58

Frankl 1

- Definitely negative
- Refusal of treatment
- Crying forcefully
- Fearful
- Overt evidence of extreme negativism



Frankl 2

- Negative
- Reluctant to accept treatment
- Evidence of negative attitude
 - Not pronounced



Frankl 3

- Positive
- Accepting of treatment
- May be cautious
- Willing to comply with dentist
- May have some reservations



61


Frankl 4

- Definitely positive
- Good rapport with the dentist and team
- Interested in dental procedures
- Laughs and enjoys the situation



Eric Petersen / The Livingston Enterprise

62



A National Vision and Dental Company

HOSPITAL / IV SEDATION REFERRAL MEMBER PROFILE

MEMBER NAME: _____

ID NUMBER: _____

PROVIDER NAME: _____

FACTORS:


1) Age	Points	4) Health complications (Documented with MD letter)	Points
Age 0 - 3	12	<i>Patient / Member could have multiple factors</i>	
Age 4 - 5	10		
Age 6 - 7	6	Autism	12
Age 8 - 9	2	Moderate Retardation	10
Age 10 +	0	Asthma / breathing problems	10
2) Services required (total of teeth to be restored and extractions)		Heart / Blood pressure problems	10
Services - 13 +	12	Mild Retardation	8
Services - 10 - 12	10	Anxiety / Situational Anxiety	5
Services - 7 - 9	8	Hysteria	5
Services - 4 - 6	6	Allergies	5
3) Previous anesthesia attempted (by GP or Pedodontist)		5) Documented Conduct Disorders (Documented with MD letter)	
Oral Sedation unsuccessful	5	ADD (313.0)	5
Nitrous Oxide unsuccessful	3	ADHD (314.0)	5
Local Anesthetic unsuccessful	1		

TOTAL POINTS _____

Scoring:
 Eligible for IV sedation 20 points or more
 Eligible for Hospital or IV sedation 30 points or more

Contact Person Name: _____
 Contact Person Phone: _____ Fax: _____

Note: Please be advised that medical conditions not specified on this form may also constitute as factors that meet criteria for hospitalization and/or IV sedation.



63

Useful (?) Drugs In Pediatric Sedation

- Nitrous oxide
- Midazolam
- Chloral hydrate
- Triazolam
- Meperidine
- Ketamine
- Morphine
- Dexmedetomidine
- Diphenhydramine
- Sufentanil
- Hydroxyzine
- Remifentanil
- Promethazine
- Propofol
- Diazepam

64

Oral Administration

- Chloral hydrate
- Meperidine
- Morphine
- Diphenhydramine
- Hydroxyzine
- Promethazine
- Diazepam
- Midazolam
- Triazolam
- Ketamine



65

Intranasal Administration

- Midazolam
- Dexmedetomidine
- Ketamine
- Sufentanil



66



Intranasal Sedation

- Midazolam 0.5 mg/kg
- Dexmedetomidine 1-2 mcg/kg
- Midazolam/ketamine
- Dexmedetomidine/ketamine
- Sufentanil/dexmedetomidine



67

Inhaled (Nebulized) Administration

- Ketamine
- Dexmedetomidine



68

Nebulized Sedation

Ketamine 2 mg/kg

Dexmedetomidine
2 mcg/kg

Dexmedetomidine/ketamine
(1 mcg/kg and 1 mg/kg)




Zanaty OM, El Metainy SA. A comparative evaluation of nebulized dexmedetomidine, nebulized ketamine, and their combination as premedication for outpatient pediatric dental surgery. *Anesth & Analg* 2015;121:167-71.

69

Chloral Hydrate

- Varied efficacy
- Dosage
 - 20 - 40 mg/kg
 - 1000 - 1500 mg maximum
- Trichloroethanol
- Adverse effects
- Myocardial sensitization
- Metabolite known carcinogen
- No longer being manufactured
 - Available through compounding pharmacies



70

Single Oral Agents

Diazepam

- .3 - .5 mg/kg

Midazolam

- .2 – 1 mg/kg
- 20 mg maximum

Triazolam

- .125 - .5 mg
- Sublingual administration increases bioavailability



71

Diphenhydramine (Benadryl)

- Dosage
 - 50-100 mg adults
 - 1.5 mg/kg children
- Onset
 - 1 hour
- Duration
 - 4-6 hours
- Contraindications
 - Allergy
- Precautions
 - Anticholinergic actions
- Availability
 - 25, 50 mg tabs and caps
 - 12.5/5 ml syrup
- No active metabolites
- Pregnancy category
 - B

72

Hydroxyzine (Vistaril)

Antiemetic/antihistaminic

CNS depression-bronchodilator, anxiolytic

Analgesia-dry mouth

Onset 15-30 minutes, working time 45 minutes, duration 2-4 hours

Availability

- 10, 25, 50, 100 mg tabs
- 10 mg/5 ml syrup
- 25 mg/5 ml syrup

Usually used with demerol or chloral hydrate

Dosage

- 1.1-2.2 mg/kg



73

Promethazine (Phenergan)

• Dosage

- 25-50 mg adults
- 1.1-2.2 mg/kg children

• Onset

- 1 hour

• Duration

- 3-4 hours

• Contraindications

- Allergy

• Precautions

- Same as for other oral sedatives

• Availability

- 12.5, 25, 50 mg tabs
- 6.25 mg/5 ml syrup
- 25 mg/5 ml syrup
- 12.5, 25, 50 mg rectal suppositories

• No active metabolites

• Pregnancy category

- C

74

Oral “Cocktails”



Meperidine/promethazine

- 1-2 mg/kg / 0.5 mg/kg

Meperidine/hydroxyzine

- 1-2 mg/kg / 1 mg/kg

Meperidine/chloral hydrate/hydroxyzine

- 1-2 mg/kg / 10 mg/kg / 1 mg/kg

Morphine/midazolam/hydroxyzine

- 1 mg/kg / 0.5 mg/kg / 1 mg/kg

Midazolam/ketamine

- .4-.7 mg/kg / 4-7 mg/kg

Success of Moderate Sedation

- Best success rate for sedation in children is 60-80%
- 20-40% will be failures
- There will always be failures when minimal/moderate sedation is employed
- Reports of serious morbidity and mortality in the dental office are based upon attempts to manage disruptive behavior with increasing dose

Moderate Sedation for Adults

Useful Drugs for Intravenous Sedation



77

Opioids

“Among the remedies which it has pleased Almighty God to give to man to relieve his sufferings, none is so universal and so efficacious as opium.”

-Sydenham, 1680



78

Opioid Receptors - 1973

- $\mu 1$
 - Analgesia (supraspinal, spinal)
 - Miosis
 - Urinary retention
 - Nausea and vomiting
 - Pruritis
- $\mu 2$
 - Sedation
 - Respiratory depression
 - GI motility decrease
- κ
 - Analgesia (supraspinal, spinal)
 - Sedation
 - GI motility decrease
 - Psychotomimesis
- σ
 - Dysphoria
 - Psychotomimesis
- δ
 - Analgesia (supraspinal, spinal)
 - Alterations of affective behavior
- Primary site of opioid activity
 - CNS
 - Bowel



79

Analgesia and Sedation

- Analgesia, drowsiness, changes in mood, mental clouding without loss of consciousness
- Relieves most types of pain regardless of origin or intensity
- Increases pain threshold
- Affective pain response is altered



80

Respiratory Effects

- Primary and continuous depressant of respiration
 - Depresses central ventilatory drive
 - Dependency on hypoxic drive
- Dose-dependent depression
- Decreases rate, tidal volume, minute volume



81

Factors Affecting Opioid-Induced Respiratory Depression


- High dose
- Elderly
 - Fewer receptors, more sensitive
 - Higher plasma concentrations on a weight basis
- Other CNS depressants
- Renal insufficiency



82

Effect on Cardiovascular Stress Response

- Attenuation
 - μ -receptor mediated action on the hypothalamic-pituitary-adrenal axis
 - Prevent ACTH release
 - Attenuate surgical stress response
 - Reduction in sympathetic tone
 - Enhance vagal and parasympathetic tone
- Hypotension and bradycardia



83

GI Effects

- Decrease gastrointestinal motility
 - Antidiarrheal effects
 - Constipation
- Reduce esophageal sphincter activity
- Delayed gastric emptying
 - “ Full stomachs” regardless of NPO status with preoperative parenteral opioids
- Stimulate the CTZ
 - δ –receptor mediated nausea and vomiting

84

Muscle Rigidity

- Increases muscle tone
 - Vocal cord closure
 - Chest-wall rigidity
 - Decrease pulmonary compliance
 - Decrease FRC
 - Increase ICP
- Usually associated with high doses and rapid administration
- Pretreatment with benzodiazepines



85

Allergic Reactions

- True allergic reactions rare
- Histamine-related wheal and flare reactions
- Dilation of cutaneous blood vessels
 - Face, neck, upper thorax flushing
- Pruritus
 - Histamine release
 - Non-histamine releasing opioids also produce pruritus
 - μ -receptor mediated
 - Facial itching common



86

Relative Potencies

	Meper	Morph	Fent	Sufent	Alfent	Remifent
Comparative Potency	0.1	1	75-125	500-1000	10-25	250
Peak Effect (min)	5-7	20-30	3-5	3-5	1.5-2	1.5-2
Duration (hr)	2-3	3-4	0.5-1	0.5-1	0.2-0.3	0.1-0.2
Half-life (hr)	3-4	2-4	1.5-6	2.5-3	1-2	0.15-0.3

87


Phenylpiperidine Series

- Meperidine
- Fentanyl
- Sufentanil
- Alfentanil
- Remifentanil

88

Meperidine (Demerol®)

- Dose 80-100 mg
- Onset 3 minutes
- Duration 45 min-1.5 hours
- Sedation
- Analgesia
- Dysphoria
- Nausea and vomiting
- Control of postop shivering
- Atropine-like effect
 - Tachycardia
 - Antisialogogue



89

Fentanyl (Sublimaze®)

- Dose 25 mcg - 100 mcg
- Onset 30 seconds
- Duration 30 minutes
- Analgesia
- No euphoria
- Respiratory depression
- Bradycardia



90

Sufentanil (Sufenta®)

- Ultrapotent
- Sedation doses
 - Dilute to final concentration of 5 mcg/ml
 - 5 mcg sufentanil is equivalent to 50 mcg fentanyl
- Dose 2.5 mcg – 10 mcg
- Onset 30 seconds




Alfentanil (Alfenta®)

- Less potent than fentanyl
- Sedation doses
 - 500 mcg alfentanil is equivalent to 50 mcg fentanyl
- Dose 250 mcg – 1000 mcg
- Onset 30 seconds




Benzodiazepines

- Benzodiazepine receptor
 - Facilitates GABA-mediated chloride ion influx
- Favorable therapeutic index
- Anxiolysis
- Sedation
- Amnesia
- Anti-convulsant
- Muscle relaxation



93

Benzodiazepines



94

Diazepam

- High lipid solubility
- Elimination half-life ranges from 22-100 hours
- Active metabolites (hangover effect)
 - Nordiazepam
 - Desmethyldiazepam
 - Oxazepam
- Soluble in propylene glycol
 - Water insoluble
 - Venous irritation (phlebitis) and pain on injection
 - Poor uptake after IM injection
- Dosing titrated to clinical endpoint



95

Midazolam

- Water soluble
 - No venous irritation or phlebitis
 - Improves IM uptake
- High lipid solubility when injected
 - Closure of benzodiazepine ring at physiologic pH
- No active metabolites
- Elimination half-life 2.5 hours
- CYP 3A4 inhibitors intensify and prolong the effects of benzodiazepines
- Dosing titrated to clinical endpoint



96

Alpha-2 Receptor Agonist


- Dexmedetomidine
- α_2/α_1 -receptor selectivity
 - Dexmedetomidine
 - 1600/1
 - Clonidine
 - 220/1



97


α_2 Adrenergic Receptor

- Adrenergic receptors
 - Regulate release of neurotransmitters
 - Control epinephrine, norepinephrine release
 - Modulate sympathetic response “negative feedback loop”




98

Mechanism of Action




Mechanism of Action

- Sites of action
 - Brain (locus ceruleus)
 - Spinal cord
 - Autonomic nerves
- CNS
 - Sedation/hypnosis
 - Anxiolysis
 - Analgesia
- Autonomic nerves
 - \downarrow Sympathetic activity
 - \downarrow BP, \downarrow HR




Respiratory Effects




101

Cardiovascular Effects



102

Cardiovascular Effects



103

Dexmedetomidine

Dexmedetomidine may potentiate the effects of other agents

- Opioids
- Sedatives/hypnotics
- Anesthetics
- Vasoactive agents

Use in conjunction with other sedatives for moderate sedation

- 0.25 mg/kg given in divided doses for desired effect to enhance sedation and smooth maintenance and emergence

104

Emergency Management and Patient Rescue

Bringing Them Back from the Precipice



105

Who is Susceptible to the Perils of Deep Sedation When Moderate Sedation is the Intent?

BMI > 35

Pediatric patients

Elderly patients

Down Syndrome patients

COPD patients

Obstructive sleep apnea patients

Opioid tolerant patients

Any patient!



106

AIRWAY MANAGEMENT

Preventing Anesthesia Morbidity and Mortality



107

Potential Causes of Office Anesthesia Deaths

- Laryngospasm
- Aspiration
- Asthma
- Allergic reaction
- Bronchospasm
- Obesity related (airway)
- OSA
- Limited mouth opening
- Anesthetic overdose
- Pulmonary embolism



108

Airway Management

- Potential for difficult airway should be anticipated
 - 90% of patients
- Unexpected problems
 - 10% of patients



109






Cardinal Signs of a Difficult Airway

- Mallampati classification III/IV
- Body mass index > 35
- History of snoring or obstructive sleep apnea
- Thyromental distance < 6 cm
- Limited mouth opening
- Receding mandibular profile
- Limited range of motion of the head and neck
- Neck circumference > 17 inches (male) > 16 inches (female)
- Craniofacial deformity
- Enlarged tonsils




110

Simplified Airway Risk Index SARI



<p>Mouth opening</p> <p>< 4 cm → 1 point ≥ 4 cm → 0 points</p> 	<p>Thyromental distance</p> <p>< 6.0 cm → 2 points 6.0-6.5 → 1 point > 6.5 cm → 0 points</p> 
<p>Mallampati</p> <p>0 points 0 points 1 point 2 points</p>  <p>The patient should not phonate, as it elevates the soft palate</p>	
<p>Neck movement</p> <p>< 80° → 2 points 80-90° → 1 point > 90° → 0 points</p> 	<p>Ability to prognath</p> <p>Yes → 0 points No → 1 point</p> 
<p>Weight</p> <p>< 90kg → 0 points 90-110kg → 1 point > 110kg → 2 points</p>	<p>History of difficult intubation</p> <p>Definite → 2 points Questionable → 1 point None → 0 points</p>

The points are summarized into the SARI score.
 A score of ≥ 4 indicates difficult direct laryngoscopy according to the Simplified Airway Risk Index.



111

Mallampati Class IV


112



113




114



115

Recognizing Airway Obstruction

116



117

Pretracheal Stethoscope

- Pretracheal positioning allows for easier recognition of respiratory sounds
- Patient-specific sizes available
- Practitioner is tethered to the patient



118

Bluetooth Pretracheal Stethoscope

- Bluetooth technology untethers the practitioner
- May be synced with remote speaker



119

Pretracheal Stethoscope

Auscultation can provide real-time information of airflow and airway patency

Breath Sounds	Interpretation
Snoring	Airway blockage by tongue/soft tissues
Gurgling	Fluids in throat/excess secretions
Wheezing	Bronchospasm
No Breath Sounds	Complete laryngospasm, bronchospasm, or obstruction



120

Utility of Carbon Dioxide Monitoring

- Is the patient breathing?
- How well is the patient breathing?
 - Adequacy of ventilation
- Diagnose airway obstruction
- Diagnose bronchospasm
- Determine adequacy of chest compressions



121




Utility of Carbon Dioxide Monitoring

- Capnography can detect airway obstruction and respiratory depression earlier than clinical exam and pulse oximetry
- May prevent oxygen desaturation




122

Sampling Devices



Capnogram





125



126

Basic Airway Maneuvers

- Head tilt/chin lift
- Jaw thrust
- Triple airway maneuver



127

Head Tilt/Chin Lift



128

Jaw Thrust



129

Triple Airway Maneuver



130



131

Dental Assistants

The Unsung Heroes of Airway Management




132



133

Dentistry as an Airway Insult



134

Airway Management Equipment

- Nasal cannulas
- Bag-valve-mask device (BVM)
- Nasopharyngeal airways
- Oropharyngeal airways
- i-gel supraglottic airways



135

Nasal Cannula

- FiO₂ increases by 4% above room air per liter of flow
- Example
 - 3 l/m x 4% = 12%
 - FiO₂ = 12% + 21% = 33%
- Patients cannot tolerate flows > 8 l/m



136

Bag-Valve-Mask (BVM) Ventilation



137

Nasopharyngeal Airways



138



139



140




141



142

Oropharyngeal Airways



143

Oropharyngeal Airway Insertion



144

i-gel Supraglottic Airway



145

i-gel Supraglottic Airway Insertion



146

Respiratory Emergencies


Laryngospasm
Bronchospasm
NPPE



147

Laryngospasm

- Spasm of the vocal cords
- Secondary to direct stimulation at the glottis
 - Water, irrigation, bleeding
 - Foreign body
 - Pain
- Treatment
 - Deep suctioning
 - Airway maneuvers
 - Larson maneuver
 - Sustained positive pressure oxygen to the airway
 - Reversal
 - Succinylcholine/rocuronium




148



149

Larson Maneuver



150



151



152

Predisposing Factors

- Asthma
- COPD
- Chronic bronchitis
- URI
- Smoker
- Progression to deep sedation



153

Preventing Laryngospasm

- Maintain consciousness
- Avoid stimulation of vocal cords
 - Secretions
 - Blood
 - Airway adjuncts



154

Complications of Laryngospasm

Hypoxia

Negative pressure pulmonary edema (NPPE)

Cardiac arrest



155

Laryngospasm and Chest Compression

4-year study of 3-12 year olds having elective tonsillectomy

First 2 years of study

- Laryngospasm treated with 100% O₂ and positive pressure ventilation via face mask

Following 2 years of study

- Laryngospasm treated with 100% O₂ and gentle chest compression

Al-Metwalli R, Mowafi H. Gentle chest compression relieves extubation laryngospasm in children. J Anesth. 2010; 24: 854-857.



156

Laryngospasm and Chest Compression

- 1226 children studied
- Chest compression group
 - 46/594 (7.8%) laryngospasm
- Standard group
 - 52/632 (8.2%) laryngospasm

Al-Metwalli R, Mowafi H. Gentle chest compression relieves extubation laryngospasm in children. J Anesth. 2010; 24: 854-857.



157

Laryngospasm and Chest Compression

- 34/46 (**73.9%**) chest compression group were successfully treated
 - NONE of chest compression group had gastric distension
- 20/52 (**38.4%**) standard group were successfully treated
 - 45/52 (86.5%) standard group developed gastric distension

Al-Metwalli R, Mowafi H. Gentle chest compression relieves extubation laryngospasm in children. J Anesth. 2010; 24: 854-857.



158

Management with Succinylcholine

Adult

- 20 mg up to 0.5 mg/kg IV
- 4 mg/kg IM
- Based on ideal body weight

Onset

- 30-60 seconds IV
- 2-3 minutes IM

Duration

- 4-6 minutes IV
- 10-30 minutes IM



159

Bronchospasm

- Constriction of the bronchial airways
- Result of debris in airway, laryngospasm, prolonged airway obstruction, or exacerbation of asthma



160

Bronchospasm Signs and Symptoms

- Cough
- Wheezing
- Dyspnea
- Increased anxiety
- Difficulty catching breath
- Patient uses accessory muscles of respiration




161



162

Small Airway Obstruction

- Acute bronchospasm
- Mucus plugging
- Partial airway obstruction
- Kinked ET tube
- Prolonged expiratory phase
- Asthma
- COPD



163

Bronchospasm Management

100% O₂ with
PEEP

Consider
reversal agents

Administer
albuterol via
BVM (10-12
puffs) with PEEP

0.3-0.5 mg
epinephrine
(1:1000)
intramuscularly

Titrate 10 mcg
epinephrine IV
until effective

Administer
albuterol via
nebulizer if non-
emergent

164

15mm O.D. Inlet

15mm I.D./22mm O.D. Outlet

Product Example

Inline MDI Adapter for Converters with a Counter

Medication

Depressed Pressurized Medicine Canister

Medication directed mainstream

Patient Wye (Not Included)

Endotracheal Tube (Not Included)

RTC 24-VP
Placed at Endotracheal Tube

165

AD0278204-200-01

Albuterol Sulfate Inhalation Solution, 0.083%*

2.5 mg/3 mL*

Each 3 mL contains 2.5 mg albuterol sulfate, equivalent to 0.083% albuterol. It is an aerosolizable solution suitable for use with a nebulizer. It is used for the treatment of bronchospasm in patients with reversible obstructive pulmonary disease. It is also used for the prevention of exercise-induced bronchospasm. It is not intended for use in patients with known hypersensitivity to albuterol or any of the other ingredients. It is not intended for use in patients with known hypersensitivity to any of the ingredients. It is not intended for use in patients with known hypersensitivity to any of the ingredients. It is not intended for use in patients with known hypersensitivity to any of the ingredients.

Rx Only

30 x 3 mL Single Dose Unit-Dose Vials, each in a foil pouch.

RTEDGSE

166

Negative Pressure Pulmonary Edema (NPPE)

Non-cardiogenic pulmonary edema

Closed upper airway is the initiating event

Increased work of breathing generates a large negative intrathoracic pressure

- -50 to -100 cmH₂O
- Normal is -3 to -10 cmH₂O

Fluid shifts from the capillaries into the pulmonary interstitial spaces

Flooding of alveoli



167

Anesthetic Causes of NPPE

- Laryngospasm
- Foreign body
- Endotracheal tube obstruction
- Bronchospasm
- **Prolonged breathing against a partially obstructed airway**
 - Increased work of breathing
 - Pediatric patients



168

Anesthetic-Related Aspiration Pneumonia

- Inhalation of oropharyngeal or gastric contents
- Oropharyngeal bacteria
 - Aspiration pneumonia
- Gastric contents
 - Aspiration or chemical pneumonitis
 - Mendelson's syndrome
 - Chemical burns to tracheobronchial tree
 - Inflammatory cell reaction release of cytokines



169

Risk Factors: Individuals With Chronically Impaired Airway Reflexes

- Alcoholism
- Drug overdose
- Deep sedation/GA
- Seizures
- Stroke
- MS
- CP
- ALS
- Down syndrome
- Parkinson's
- Myasthenia gravis
- GERD



170

Clinical Presentation

Chemical Pneumonitis

- Acute onset
- Respiratory distress
- Wheezing or cough
- Pink, frothy sputum

Aspiration Pneumonia

- Subacute or insidious onset
- Non-specific symptoms
- Shortness of breath
- Dyspnea on exertion



171

Treatment

Chemical Pneumonitis

- Airway maintenance
- Clearance of secretions
- Supplemental oxygen
- Immediate transport
- Intubation with mechanical ventilation and PEEP
- Routine use of steroids and prophylactic antibiotics not recommended

Aspiration Pneumonia

- Antibiotics if failure to resolve within 48 hours



172

Cardiovascular Issues

Acute Coronary Syndromes

Hypotension

Hypertension

Dysrhythmias



173


MI

- Chest pain, tightness, pressure, lasting more than 15 minutes and not alleviated by NTG
- Radiating pain to the shoulders, neck, arms, or jaw
- Diaphoresis, nausea, vomiting
- Stress, anxiety, impending doom
- **ST-segment elevation or new LBBB**
 - **STEMI**
- **ST-segment depression**
 - **NSTE-ACS**
- Manage with OANM
 - Oxygen, aspirin, nitroglycerine, morphine



174

Acute Coronary Syndromes



©Bayer Pharma AG
www.thrombosisadviser.com



175

Acute Coronary Syndromes

Oxygen

- If SpO₂ < 90%

Aspirin

- 160 – 325 mg non-enteric coated orally, crushed or chewed

Nitroglycerin

- Contraindicated if SBP < 90 mmHg or > 30 mmHg below baseline
- Bradycardia < 50
- Tachycardia > 100
- Phosphodiesterase inhibitor

Nitroglycerine dose

- SL .4 mg repeat x 2
- Spray 1 or 2 sprays x 2

Morphine

- 2 – 4 mg IV




176

End-Organ Autoregulation

Process by which tissues control their own blood flow


Requires minimum threshold

Insufficient pressure gradient for perfusion below minimum threshold



177

Detrimental Effects of Hypotension in Patients with Hypertension



178

Etiology of Intraoperative Hypotension

- Effect of anesthetic agents
- Hypovolemia
 - Blood loss or dehydration (NPO status)
- Position of surgical technique
 - Upright or beach chair--> cerebral ischemia
- Cardiac etiology (pump failure)
- Pathologic maldistribution of blood flow (shock or anaphylaxis)
- No widely accepted definition of intraoperative hypotension,
 - A decrease of SBP > 20% is often chosen to define perioperative hypotension



179

Complications of Intraoperative Hypotension

Acute kidney injury

Myocardial injury

Stroke

Delirium

Mortality



180

Relationship Between Intraoperative MAP and Clinical Outcomes After Noncardiac Surgery

- 33,330 noncardiac surgeries
- Evaluated association between intraop MAP <55 mmHg and postop acute kidney injury, myocardial injury, cardiac complications
- Even short durations (1-5 min) of an intraoperative MAP of <55 mmHg are associated with AKI and myocardial injury
- Risk escalates rapidly and there is no safe duration for MAP <55 mmHg
- 30 day mortality was associated with more than 20 min of MAP <55 mmHg



Walsh M, Devereaux PJ, Garg AX, et al. Relationship between intraoperative mean arterial pressure and clinical outcomes after noncardiac surgery: toward an empirical definition of hypotension. *Anesthesiology* 2013;119(3):507-515

181

Hypotension During Anesthesia

Patients with no cardiovascular impairments

- 2/3 MAP

Patients with cardiovascular impairments

- Maintain MAP as close to baseline as possible
- 80% of baseline MAP

Semi-reclining or sitting position

- Cerebral pressure may be 12-16 mmHg lower than arm



182

Hypotension Treatment

Order of Treatment:

- Check pulse and monitors
- Fluids
- Treat with IV vasopressor/inotrope
- Consider Trendelenburg position
- Decrease depth of anesthesia

Indication for vasopressor/inotrope

- >30mmHg lower than baseline systolic BP
- MAP < 60 mmHg
- MAP < 80% of baseline

183

Management of Hypotension

- Normal to slow heart rate
 - Ephedrine 5-10 mg to effect
- Normal to fast heart rate
 - Phenylephrine 100 mcg to effect
- Epinephrine 10 mcg to effect

184

Hypertension

Most common reason for postponing surgery

Risk of perioperative cardiac catastrophe

DBP > 110 associated with dysrhythmia, myocardial ischemia and infarction, renal failure, neurological complications

MAP > 120% of baseline may lead to bleeding, CVA, myocardial ischemia and infarction

MAP < 80% of baseline may lead to end-organ malperfusion



185

Management of Hypertension

Differential

- Pain
- Hypercarbia
- Emergence phenomenon
- Bladder distention

Normal to slow heart rate

- Hydralazine 10-20 mg to effect

Normal to fast heart rate

- Labetalol 5 mg to effect
- Metoprolol 1mg to effect

186

Dysrhythmias

Bradycardia that causes hypotension

- Atropine 0.5 mg – 1.0 mg IM

Irregular rhythms

- Abort procedure if more than 5 irregular beats per minute and refer to physician for evaluation
- Amiodorone 150 mg IV over 10 minutes
- 150 mg in 100 ml D5W

Tachyarrhythmias (SVT)

- Adenosine 6 mg fast IV push with flush
- For both narrow and wide complex tachycardia


187

Reversal

188



189




TEN MINUTES SAVES A LIFE!

Considerations for Office Medical Emergency Drugs, Supplies, and Equipment

The goal of the Ten Minutes Saves A Life™ ADASA Anesthesia Research Foundation initiative is to optimize patient safety and outcomes in office medical emergencies. This program supports crisis resource management team training in the use of emergency drugs and equipment during the critical ten minute interval between recognition of a patient's medical emergency and arrival of EMS (emergency medical service) personnel. Practitioners should be familiar with the suggested emergency drugs/ equipment and have them immediately available.

Anesthesia Research Foundation




American Dental Society of Anesthesiology




190

Ten Minutes Saves a Life



191

Ten Minutes Saves a Life



192

Ten Minutes Saves a Life

Local Anesthetic Calculator
 Chart for adult patients. Pediatric AAPD Guidelines in chart below.
 AAPD guidelines have lower maximum dose than the manufacturer's package insert.

Manufactures package insert calculation

Type	Max Dose (mg/kg)	MAX Calc (mg)	Absolute MAX Cartridge #	% MAX Used
Articaine: 4% w/ epinephrine Note: Age > 4 y.o.	7.0	0	0.0	0%
Lidocaine: 2% w/ epinephrine Note: Age > 4 y.o.	7.0 up to 500mg	0	0.0	0%
Mepivacaine: 3% plain	6.6 up to 400mg	0	0.0	0%
Mepivacaine: 2% w/ levonordefolil	6.6 up to 400mg	0	0.0	0%
Prilocaine: 4% plain	8.0 up to 600mg	0	0.0	0%
Prilocaine: 4% w/ epinephrine	8.0 up to 600mg	0	0.0	0%
Bupivacaine: 0.5% w/ epinephrine Note: Age > 12 y.o.	Total up to 90 mg	0	0.0	0%
Total %			0.0	0%

AAPD guidelines calculation

Type	Max Dose (mg/kg)	MAX Calc (mg)	Absolute MAX Cartridge #	% MAX w/ 2% Mepivacaine	% MAX w/ 4% Articaine	% MAX w/ 2% Mepivacaine	% MAX w/ 2% Lidocaine
Articaine: 4% w/ epinephrine Note: Age > 4 y.o.	7.0	0	0.0	0%	0%	0%	0%
Lidocaine: 2% w/ epinephrine Note: Age > 4 y.o.	7.0 up to 500mg	0	0.0	0%	0%	0%	0%
Mepivacaine: 3% plain	6.6 up to 400mg	0	0.0	0%	0%	0%	0%
Mepivacaine: 2% w/ levonordefolil	6.6 up to 400mg	0	0.0	0%	0%	0%	0%
Prilocaine: 4% plain	8.0 up to 600mg	0	0.0	0%	0%	0%	0%
Prilocaine: 4% w/ epinephrine	8.0 up to 600mg	0	0.0	0%	0%	0%	0%
Total %			0.0	0%	0%	0%	0%

193


Ten Minutes Saves a Life

Medication List:

- Emergen 150 mg
- Dilantin 25 g
- Adrenalin 6 mg
- Dilantin 12 mg
- Albuterol inhaler 90 mcg
- Amoxicillin IV (Clav) 300 mg
- Amoxicillin IV (Lactacycline) 150 mg
- Aspirin PO 325 mg
- Atropine IV 0.5 mg
- Dantrolene IV 250 mg
- Dilantin IV 1000 mg
- Dilantin IV (IM only) 5 mg
- Diphenhydramine IV/IM/IV 50 mg
- Ephedrine IM (IV/bid) 3 mg
- Ephedrine IV (Adult) 10 mg
- Epinephrine IM 300 mcg
- Epinephrine IV 10 mcg
- Epinephrine IV (Cardiac Arrest) 1 mg
- Etoricoxib IV 60 mg
- Fentanyl IV 25 mcg
- Fentanyl IV (Adult) 0.5 mg
- Fentanyl IV (IV/bid) 0.5 mg
- Furosemide IV 40 mg
- Hydrocortisone IV 5 mg
- Lidocaine IV 150 mg
- Lidocaine IV 75 mg
- Midazolam IM 10 mg
- Midazolam IV/IM 5 mg
- Morphine IV 5 mg
- Naloxone IV/IM 2 mg
- Nitroglycerin PO (Adult) 0.4 mg
- Oxycodone IV 4.0 mg
- Propofol IV 50 mg
- Propofol IV (Adult) 50 mcg
- Propofol IV 20 mg
- Sotalolol IV 136 mg
- Succinylcholine IM 100 mg
- Succinylcholine IV 20 mg
- Tyne cardiovascular (see info) 50-100 J

194


Ten Minutes Saves a Life



195

“No one ever died in a conscious state.”

Dr. Leonard M. Monheim



196